MIRA vs. AEZS, MNPR, GRTX, AVTX, ELAB, NCNA, GHSI, CMMB, MBRX, and ABVC
Should you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Aeterna Zentaris (AEZS), Monopar Therapeutics (MNPR), Galera Therapeutics (GRTX), Avalo Therapeutics (AVTX), Elevai Labs (ELAB), NuCana (NCNA), Guardion Health Sciences (GHSI), Chemomab Therapeutics (CMMB), Moleculin Biotech (MBRX), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical preparations" industry.
Aeterna Zentaris (NASDAQ:AEZS) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
MIRA Pharmaceuticals has lower revenue, but higher earnings than Aeterna Zentaris. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.
MIRA Pharmaceuticals has a net margin of 0.00% compared to MIRA Pharmaceuticals' net margin of -760.32%. MIRA Pharmaceuticals' return on equity of -73.62% beat Aeterna Zentaris' return on equity.
Aeterna Zentaris currently has a consensus price target of $60.00, indicating a potential upside of 604.23%. Given MIRA Pharmaceuticals' higher possible upside, equities analysts plainly believe Aeterna Zentaris is more favorable than MIRA Pharmaceuticals.
In the previous week, MIRA Pharmaceuticals had 3 more articles in the media than Aeterna Zentaris. MarketBeat recorded 10 mentions for MIRA Pharmaceuticals and 7 mentions for Aeterna Zentaris. MIRA Pharmaceuticals' average media sentiment score of 0.20 beat Aeterna Zentaris' score of -0.23 indicating that Aeterna Zentaris is being referred to more favorably in the media.
0.7% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 0.1% of Aeterna Zentaris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Aeterna Zentaris received 419 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users.
Summary
Aeterna Zentaris beats MIRA Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get MIRA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MIRA Pharmaceuticals Competitors List
Related Companies and Tools
